Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Evogene Ltd. Regulatory Filings 2024

Sep 25, 2024

6785_rns_2024-09-25_94675b3f-1a13-42aa-9951-9e3a11f62b32.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

CORRESP 1 filename1.htm Licensed to: ZKG Document created using Broadridge PROfile 24.8.1.5246 Copyright 1995 - 2024 Broadridge

Evogene Ltd.

13 Gad Feinstein Street, Park Rehovot

Rehovot 7638517, Israel

September 25, 2024

VIA EDGAR

United States Securities and Exchange Commission Division of Corporation Finance

Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549

Attention : Conlon Danberg

Re:
Registration Statement on Form F-1
Filed September 19, 2024 File No. 333-282218

Dear Mr. Danberg:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Evogene Ltd. hereby requests that the effective date of the above-referenced Registration Statement on Form F-1 be accelerated so that it will become effective at 9:00 a.m. Eastern time on September 27, 2024, or as soon as practicable thereafter.

Please contact our outside counsel, Meitar Law Offices (Mike Rimon, Adv. at +972-3-6145822 or [email protected] , Jonathan M. Nathan, Adv. at +972-3-610-3157 or [email protected] , or Elad Ziv, Adv. at+972-3-6142613 or [email protected] ) with any questions, and please notify them when this request for acceleration has been granted.

Sincerely,
EVOGENE LTD.
By: /s/ Ofer Haviv
Name: Ofer Haviv
Title: President and Chief Executive Officer
cc: Meitar Law Offices Mike Rimon, Adv.
Jonathan M. Nathan, Adv. Elad Ziv, Adv.